ECSP18087725A - 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas - Google Patents

3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas

Info

Publication number
ECSP18087725A
ECSP18087725A ECSENADI201887725A ECDI201887725A ECSP18087725A EC SP18087725 A ECSP18087725 A EC SP18087725A EC SENADI201887725 A ECSENADI201887725 A EC SENADI201887725A EC DI201887725 A ECDI201887725 A EC DI201887725A EC SP18087725 A ECSP18087725 A EC SP18087725A
Authority
EC
Ecuador
Prior art keywords
compounds
diphenyl
oxo
preparing
pharmaceutical compositions
Prior art date
Application number
ECSENADI201887725A
Other languages
English (en)
Inventor
Lars Roese
Ilona Gutcher
Ulrike Roehn
Michael Platten
Benjamin Bader
Norbert Schmees
Detlef Stoeckigt
Na Zhao
Horst Irlbacher
Ludwig Zorn
Original Assignee
Deutsches Krebsforschungszentrum Dkfz
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum Dkfz, Bayer Pharma AG filed Critical Deutsches Krebsforschungszentrum Dkfz
Publication of ECSP18087725A publication Critical patent/ECSP18087725A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención cubre compuestos de 3–oxo–2,6–difenil–2,3–dihidropiridazin–4–carboxamida de fórmula general (I): en la cual R1, R2, R3, R4, R5 y R6 son según lo definido en la presente invención, métodos para preparar dichos compuestos, compuestos intermedios útiles para preparar dichos compuestos, composiciones y combinaciones farmacéuticas que comprenden dichos compuestos y la utilización de dichos compuestos para manufacturar composiciones farmacéuticas para el tratamiento o profilaxis de enfermedades, en particular del cáncer o afecciones con respuestas inmunes desreguladas u otros trastornos asociados con la señalización aberrante del AHR, como un agente único o en combinación con otros ingredientes activos.
ECSENADI201887725A 2016-05-25 2018-11-23 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas ECSP18087725A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016083308 2016-05-25
CN2017074408 2017-02-22

Publications (1)

Publication Number Publication Date
ECSP18087725A true ECSP18087725A (es) 2018-11-30

Family

ID=58745251

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201887725A ECSP18087725A (es) 2016-05-25 2018-11-23 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas

Country Status (28)

Country Link
US (1) US11040035B2 (es)
EP (1) EP3464248B1 (es)
JP (1) JP6964096B2 (es)
KR (1) KR20190009369A (es)
CN (1) CN109863140B (es)
AU (1) AU2017269870A1 (es)
BR (1) BR112018074185A2 (es)
CA (1) CA3025227A1 (es)
CL (1) CL2018003345A1 (es)
CO (1) CO2018012654A2 (es)
CR (1) CR20180556A (es)
CU (1) CU20180143A7 (es)
DO (1) DOP2018000256A (es)
EA (1) EA201892666A1 (es)
EC (1) ECSP18087725A (es)
IL (1) IL263046A (es)
JO (1) JOP20170126A1 (es)
MA (1) MA45087A (es)
MX (1) MX2018014443A (es)
NI (1) NI201800124A (es)
PE (1) PE20190509A1 (es)
PH (1) PH12018502472A1 (es)
SG (1) SG11201810366WA (es)
SV (1) SV2018005787A (es)
TN (1) TN2018000392A1 (es)
TW (1) TW201742859A (es)
UY (1) UY37256A (es)
WO (1) WO2017202816A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
US12522594B2 (en) * 2017-02-09 2026-01-13 Deutsches Krebsforschungszentrum 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
EP3713931B1 (en) * 2017-11-21 2025-03-05 Deutsches Krebsforschungszentrum 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
EA037978B1 (ru) * 2017-11-21 2021-06-18 Байер Акциенгезельшафт 2-гетероарил-3-оксо-2,3-дигидропиридазин-4-карбоксамиды для лечения злокачественного новообразования
US11524944B2 (en) 2017-11-21 2022-12-13 Bayer Aktiengesellschaft 2-phenylpyrimidine-4-carboxamides as AHR inhibitors
WO2019101642A1 (en) * 2017-11-21 2019-05-31 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
US12221439B2 (en) 2018-08-24 2025-02-11 Jaguahr Therapeutics Pte Ltd Tetrahydropyridopyrimidine derivatives as AhR modulators
US20210395242A1 (en) 2018-08-31 2021-12-23 Jaguahr Therapeutics Pte Ltd Heterocyclic compounds as ahr modulators
CN109771437B (zh) * 2019-03-28 2023-03-17 西安交通大学医学院第一附属医院 三氟胸苷在制备治疗三阴性乳腺癌药物中的应用
EP3715471A1 (en) * 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3721894A1 (en) 2019-04-10 2020-10-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof
JP7636326B2 (ja) * 2019-07-29 2025-02-26 武田薬品工業株式会社 複素環化合物
EP3835432A1 (en) 2019-12-10 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer
BR112022007837A2 (pt) * 2019-12-16 2022-07-05 Bayer Ag Combinação de um inibidor de ahr e um anticorpo inibidor de pd1 e seu uso no tratamento de câncer
BR112022013673A2 (pt) 2020-01-10 2022-09-13 Ikena Oncology Inc Inibidores de ahr e seus usos
JP2023515128A (ja) 2020-02-26 2023-04-12 ジャガー セラピューティクス ピーティーイーリミテッド Ａｈｒシグナル伝達の調節に有用なピリドピリミジン誘導体
BR112022019387A2 (pt) * 2020-03-27 2022-11-16 Dong A St Co Ltd Derivados de aminopirimidina e seu uso como moduladores de receptores de aril hidrocarbonetos
US11911376B2 (en) 2020-03-30 2024-02-27 The Regents Of The University Of Colorado Methods for preventing and treating retinal damage
WO2021236717A1 (en) 2020-05-20 2021-11-25 Senda Biosciences, Inc. Fused imidazole derivatives as ahr antagonists
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN114369097B (zh) * 2020-10-15 2023-07-14 山东轩竹医药科技有限公司 杂芳环类AhR抑制剂
CN114685426B (zh) * 2020-12-28 2026-05-26 苏州泽璟生物制药股份有限公司 磺酰胺类抑制剂及其制备方法和应用
WO2023043753A1 (en) * 2021-09-14 2023-03-23 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders
CN119948035A (zh) 2022-10-03 2025-05-06 捷豹治疗有限公司 可用于调节AhR信号传导的化合物
WO2025114771A1 (en) 2023-11-29 2025-06-05 Latvian Institute Of Organic Synthesis A new class of aryl hydrocarbon receptor antagonists and their optimisation
WO2026027421A1 (en) 2024-07-30 2026-02-05 Leibniz-Institut Für Pflanzenbiochemie 4-oxo-1,4-dihydropyridazine derivatives as aryl hydrocarbon receptor agonists for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU756275B2 (en) * 1998-08-14 2003-01-09 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives
JP4233868B2 (ja) * 2000-09-18 2009-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリダジノンおよびトリアジノン化合物類ならびにそれらの医薬用途
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
FR2847235B1 (fr) 2002-11-20 2005-07-08 Essilor Int Emballage de protection et de calage pour objets a contour circulaire
AR057986A1 (es) 2005-11-21 2008-01-09 Japan Tobacco Inc Compuesto heterociclico y su uso farmaceutico
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US10314810B2 (en) 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
WO2015143164A1 (en) * 2014-03-19 2015-09-24 President And Fellows Of Harvard College Antimicrobial agents and screening methods
US12522594B2 (en) * 2017-02-09 2026-01-13 Deutsches Krebsforschungszentrum 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Also Published As

Publication number Publication date
KR20190009369A (ko) 2019-01-28
SV2018005787A (es) 2019-02-07
MA45087A (fr) 2021-05-26
SG11201810366WA (en) 2018-12-28
EP3464248A1 (en) 2019-04-10
AU2017269870A1 (en) 2018-12-06
CO2018012654A2 (es) 2018-12-14
CU20180143A7 (es) 2019-07-04
US11040035B2 (en) 2021-06-22
TW201742859A (zh) 2017-12-16
PE20190509A1 (es) 2019-04-10
EP3464248B1 (en) 2021-09-08
UY37256A (es) 2018-01-02
TN2018000392A1 (en) 2020-06-15
JP6964096B2 (ja) 2021-11-10
EA201892666A1 (ru) 2019-08-30
CR20180556A (es) 2019-04-23
CN109863140B (zh) 2023-02-21
JOP20170126A1 (ar) 2017-11-25
DOP2018000256A (es) 2019-02-15
IL263046A (en) 2018-12-31
WO2017202816A1 (en) 2017-11-30
JP2019516744A (ja) 2019-06-20
US20200237757A1 (en) 2020-07-30
MX2018014443A (es) 2019-04-15
PH12018502472A1 (en) 2019-09-23
BR112018074185A2 (pt) 2019-03-06
NI201800124A (es) 2019-04-29
CN109863140A (zh) 2019-06-07
CL2018003345A1 (es) 2019-03-15
CA3025227A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
NI201800124A (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
CR20190364A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
PH12017502001A1 (en) Amido-substituted cyclohexane derivatives
UY37971A (es) Derivados de indol macrocíclicos sustituidos
PH12016501807A1 (en) Novel compounds
PH12017501133A1 (en) Pyrazolopyridinamines
UY37973A (es) Derivados de indol macrocíclicos
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
CL2019001004A1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos.
BR112017003227A2 (pt) composto, composição farmacêutica e uso de um composto
UY35600A (es) "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"
UY37032A (es) Compuestos de heteroarilbenzimidazol
MA39762A (fr) Nouveaux composés